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Abstract
Based on the tumor growth model of Harald Weedon-Fekjær et al.'s pa-
per "Breast cancer tumor growth estimated through mammography screening
data", a simulation of breast cancer occurrence and tumor growth in a large
population of women was made. The simulation was made realistic by start-
ing tumor growth according to a Poisson process, including a distribution for
clinical detection size and a screening test sensitivity function, and using an
individual growth rate, κ, based on estimates of Weedon-Fekjær et al. [1]
After running the full simulation, parts of the simulation outcomes were
compared to known data of breast cancer and the model was found to give
realistic and expected results. The simulation was then used to look for other
interesting results such as expected reduction in time to tumor detection due to
screening and ﬁnding the size distribution of tumors before and after screening.
For the age group 50 - 69 years, it was found that screening every year allows
a reduction of 19.1 months, while screening every two, three, ﬁve and ten years
allows for reductions of, respectively, 9.5, 8.3, 6.1 and 3.4 months. These results
are based on the assumption that tumors are actually found at screening, i.e.
the tumors are not found clinically before they are found on screening.
When clinical ﬁndings are included, diﬀerent results are obtained. For the age
group 50 - 69 years, it was found that screening every year allows a reduction
of 15 months, while screening every two, three, ﬁve and ten years allows for
reductions of, respectively, 4.8, 1.4, -5.6 and -21.5 months. Negative numbers
indicate that a tumor is found earlier clinically than at screening.
To my grandmother Wilhelmina, looking down at me so proud.
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Main introduction
Based on data from 2002, 10.9 million people worldwide are diagnosed with cancer
every year and there are 6.7 million deaths from cancer [2]. One in ten of all new
cancers diagnosed, and close to one in four cancers diagnosed in women worldwide,
is a cancer of the breast. More than 1.1 million women are diagnosed each year and
breast cancer is the main cause of death from cancer in women globally [3].
The Cancer Registry of Norway (CRN) is one of the oldest national cancer reg-
istries in the world. By law, all new cancer cases must be notiﬁed to the CRN,
which makes the registry unique. The Norwegian Breast Cancer Screening Program
(NBCSP) is one of the two screening programs organized by the CRN. The NBCSP
obtained national coverage in 2004. The program invites all women between 50 and
69 years of age to mammography screening every two years. The idea behind breast
cancer screening, is to detect a tumor earlier than it would have been without screen-
ing and therefore be able to diagnose the patient at an earlier stage. The eﬀects of
screening is a topic still undergoing discussion.
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Figure 1: The full path of seven breast cancer tumor growth curves, with diﬀerent
growth rates
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In Harald Weedon-Fekjær et al.'s [1] article "Estimating tumour growth and
screening test sensitivity", a model for breast cancer tumor growth was presented.
The model is based on previous work by Spratt et al. [4], among others. Weedon-
Fekjær presents a tumor growth function including an individual growth rate, which
makes it possible to simulate the full path of a breast cancer tumor's development.
An example of seven growth curves, each with a diﬀerent growth rate, is given in
ﬁgure 1. This is the point departure for this thesis.
In this thesis, a synthetic population based on the estimated model will be stud-
ied. This has many advantages, as things like screening frequencies and population
characteristics easily can be varied. Also, when or how a tumor is detected can be
changed. These modiﬁcations give a unique possibility to investigate matters that
are usually not available for research from real data, for example how much earlier a
tumor could be detected with screening than without.
The ﬁrst part of this thesis consists of a theoretical background. Diﬀerent as-
pects of cancer mammae (breast cancer) are provided, previous work on modeling of
breast cancer and diﬀerent parameters needed in the models are presented and a few
statistical methods are described.
The second part gives a short presentation of the statistical programming language
R and an overview of how the simulation works.
In part three, the results of the simulation are presented, the results are discussed
and the conclusion is given.
The last part is an appendix containing some of the R-code used in the simulation.
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Part I
Theory
Introduction
The goal of this part, is to describe the theory behind the steps needed to make a
realistic simulation of cancer mammae in a Norwegian female population. A short in-
troduction of cancer mammae will be given, models explained and statistical methods
presented.
1 Cancer mammae
1.1 What is cancer?
Cancer occurs in the body when cells start growing without regulation and the tumor
created invades surrounding tissue. When cells grow unrestrained, they are often
called cancer cells and a tumor consisting of cancer cells, is called a malignant tumor.
1.2 Cancer mammae
Cancer mammae is cancer of the breast, and in daily language mostly referred to
as breast cancer. The breast consists of fatty-, glandular- and connective tissue. In
women, the breast also contains mammary glands (milk glands) and lactiferous ducts
(milk ducts). About 80 % of all cancer mammae cases, originate in the lactiferous
ducts, while 10-15 % of the cases occur in the mammary glands [5]. This diﬀerence
in anatomy is one of the reasons cancer mammae is by far more common in women
than in men. In women, cancer mammae is the most common type of cancer.
Cancer cells that emerge in the breast tissue, mostly originate in the breast it self;
spreading of cancer cells from other organs to the breast is very rare. On the other
hand, if a malignant tumor in the breast grows into a blood- or lymphatic vessel,
cancer cells may unfasten and be carried with the blood- or lymph stream to other
locations in the body, called metastasis.
Cancer mammae is characterized by a great variation in progression; from fast
growing tumors that spread to other organs (metastasis) to slow growing tumors
without metastasis. In 25-30% of the cases, the tumor is aggressive [6].
Experience shows that younger women, on average, have more aggressive forms of
cancer mammae then older women.
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Figure 2: Average number of annual new cases of cancer mammae in a) women and
b) men from 1957-2006
Table 1: Average number of annual new cancer mammae cases in Norwegian men and
women from 1957 - 2006, in ﬁve years intervals
1957-61 1962-66 1967-71 1972-76 1977-81
Men 7 8 9 10 11
Women 937 1066 1224 1410 1538
1982-86 1987-91 1992-96 1997-01 2002-06
Men 12 13 13 15 16
Women 1734 1844 2082 2475 2735
1.3 History of cancer mammae
According to the report "Cancer in Norway 2006" [7] there were 2687 new cases of
cancer mammae in Norway in 2006, where 2673 cases were in women and 14 in men.
Table 1 and Figure 2 show the number of new cases of cancer mammae in Norway
the last 50 years. As seen, there has been a strong increase of new cases.
Table 2 shows the number of annual new cases the last ten years. Comparing table
1 and Table 2, it can be seen that although there has still been an increasing trend the
last ten years, it has not been as strong as earlier. In 2006 there was even a decrease
in number of annual new cases for the ﬁrst time in many years.
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Table 2: Number of annual new cancer mammae cases in Norwegian men and women
from 1997 - 2006
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Men 11 21 14 17 13 14 20 14 18 14
Women 2401 2416 2408 2528 2621 2694 2723 2787 2799 2673
1.4 Risk factors
Some known factors that increase the risk of cancer mammae are:
• Sex (being female)
• Increasing Age
• Inheritance (Close relatives; mother, daughter, sister and grandmother)
• Hormonal conditions (Early menstruation, late ﬁrst birth, childlessness and late
menopause)
• Case history (Cancer in one breast, increases chance of cancer in the other
breast)
• Long time use of estrogen therapy before menopause
• Excessive weight after menopause, especially for tall women
• Alcohol.
Behind sex, the most prominent risk factor for developing cancer mammae is
increasing age. Table 3 and Figure 3 show the age distribution of annual new cases
in 2006. At a young age, the probability of developing cancer mammae is fairly low,
but risk increases rapidly from age 40-44 in women, and somewhat later in men, to
the highest risk at age 60-64 in women.
An interesting ﬁnding is the drop in number of annual new cases around age 70.
The drop is a result of women leaving the oﬃcial screening program which runs from
age 50 to 69. A new drop can be seen at age 80+. This drop can be explained by the
lack of detection of disease in elderly, as they often decease from other causes.
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Table 3: The age distribution of new cases of cancer mammae in 2006
0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44
Men 0 0 0 0 0 0 0 0 0
Women 0 0 0 0 4 3 36 75 167
45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Men 0 0 0 2 3 3 2 3 1
Women 295 345 351 369 290 163 175 195 205
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Figure 3: The distribution of new cancer mammae cases in diﬀerent age groups
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1.5 Risk reduction
Similar to factors that increase the risk of cancer mammae, there are also factors that
may reduce the risk:
• First pregnancy at young age ( < 20-25 years)
• Several births at young age ( < 25 years)
• Asian descent
• Regular exercise.
1.6 Signs and symptoms
Usually, the ﬁrst and most prominent symptom of cancer mammae is a tumor, which
can be felt as a lump in the breast or armpit. Other symptoms may include chest
pain, ﬂuid from the nipple, changes in the nipple, skin change and open wounds, but
these are less common. In cases that have existed for a long time before diagnosis,
symptoms of back- and chest pain are sometimes signs of metastasis. Shortness of
breath could indicate metastasis to the lungs and nausea and stomach pain may be
a sign of metastasis to the liver.
(a) Normal (b) Benign (c) Malignant
Figure 4: Mammography pictures of breasts without a tumor, with a benign tumor
and a malignant tumor. Source: http://www.pasienthandboka.no/
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Figure 5: The idea behind screening
1.7 Screening by mammography
Mammography is a x-ray photo of the breast. Figure 4 shows mammography images
of a normal breast 4(a), a breast with a benign tumor 4(b) and a breast with a
malignant tumor 4(c).
Screening is a term used to describe diﬀerent types of examinations that are
performed on a large number of individuals. Diseases that are screened for, are often
rare, but if found at an early stage, treatment is thought to be more eﬃcient.
Figure 5 shows the idea of mammography screening for cancer mammae. At any
given time, a tumor might start growing, marked 'onset of cancer'. The tumor will
start growing, slow or fast, depending on factors such as age. Reaching a certain size,
the tumor is large enough to be visible on mammography. In most cases, this occurs
before clinical signs can be detected, and before any symptoms are present.
So, the idea behind screening by mammography, is to detect the tumor when it
is large enough to be found at mammography, but before the tumor gives clinically
detectable symptoms. The time spent in this phase is called sojourn time.
The overall mean sojourn time (MST) has been estimated by Weedon-Fekjær et
al. [1] to be 2,9 years among all cases and signiﬁcantly longer in older women. Earlier
diagnosis opens for earlier treatment which could give, a better prognosis.
Figure 6 shows the size distribution of tumors found at ﬁrst screening for women
reporting no earlier screening history.
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Figure 6: The size distribution of tumor diameters found at screening. Data from the
Norwegian Breast Cancer Screening Program (1995-2002). Figure from Weedon-Fekjær et al.
[1]
1.8 Other diagnostics and treatment
Diagnostics of cancer mammae is not done by mammography screening alone. Clinical-
and self-examinations are also important diagnostic tools. When a lump or irregularity
is found, either by mammography or examination, additional inspection is needed.
Ultrasound is an important supplement to mammography and in special cases mag-
netic tomography (MR) is used. If the preliminary tests indicate a malignant tumor, a
needle biopsy is performed. A ﬁnal cancer diagnosis can only be given by examination
of a tissue sample under a microscope.
The treatment of cancer mammae depends on signs of metastases. Local tumors
without signs of metastases can be removed by surgery alone, with good eﬀect. In
other cases treatment, alone or in combination, consist of radiation therapy, hormone
therapy and chemotherapy.
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1.9 The Cancer Registry of Norway and the Norwegian Breast
Cancer Screening Program
The Cancer Registry of Norway (CRN) was established in 1951. It is one of the oldest
national cancer registries in the world. By law, all new cancer cases must be notiﬁed
to the CRN. This makes the registry unique.
The Norwegian Breast Cancer Screening Program (NBCSP) is one of the two
screening programs organized by the CRN. The NBCSP started in four Norwegian
counties in 1995 and was gradually introduced to the rest of the counties until full
coverage was obtained in 2004. The program invites all women between 50 and 69
years of age to mammography (see section 1.7) every two years.
1.10 Hormone replacement therapy and NBCSP data collec-
tion
Hormone replacement therapy (HRT) is a drug used to reduce physical disturbances
associated with menopause in women. Early research showed a protective eﬀect of
HRT use, especially against cardiovascular disease, but also against other severe health
problems. Because of the increased belief in a protective eﬀect, HRT use increased
rapidly until the late 1990s. In 2002 the Women's Health Initiative study reported an
increased risk of both breast cancer and cardiovascular disease in a large randomized
trial [8] and HRT use dropped.
Figure 7 shows annual Norwegian sales of HRT drugs. As indicated, the NBCSP
data used to estimate the parameters in Weedon-Fekjær et al.'s [1] model, were col-
lected at the same time HRT use was at its peak.
Weedon-Fekjær et al. corrected their data for the extended use of HRT-drugs at
the time of data collection.
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Figure 7: Use of hormone replacement therapy (HRT) in Norway from 1987 to 2006,
in daily doses. The collection of data used to estimate the Weedon-Fekjær et al.'s [1]
model parameters, were collected from 1995 to 2002. Figure from Weedon-Fekjær et al. [1]
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2 Previous work
2.1 Models
Since cancer mammae is one of the most common types of cancer in women, espe-
cially in the western world, several attempts have been made to simulate the growth
of breast cancer tumors. Looking back to Figure 5, knowledge of the growth of these
tumors is interesting because it can help us determine when a tumor is in the scram-
bled area; large enough to be detected at screening by mammography, but before it
gives clinical symptoms.
Modeling of cancer mammae tumor growth has been done in diﬀerent ways. Two
main methods have been used in the past; a Markov chain model with appurtenant
transition probabilities, and assigning a distribution to the size of the tumor as a
function of time. Also, a computer simulation program, MISCAN, has been used to
model cancer mammae.
The Markov model One way to deﬁne a basic Markov model of screening related
cancer progression, is a three state model thoroughly studied by S. W. Duﬀy et al.
[9] - [11]. The diﬀerent states of a basic Markov model are shown in Figure 8.
Figure 8: The three states of a basic Markov model. Figure from Weedon-Fekjær et al. [1]
MISCAN-Fadia MISCAN [12] is a computer simulation program developed for
building models for cancer screening. The models are used to analyze and explain
results of cancer screening trials, to predict and compare the (cost-) eﬀectiveness
of diﬀerent screening policies, and to monitor the results of population screening
programs.
The MISCAN-Fadia model includes the concept of a "fatal diameter" of cancer
mammae tumors. The model has been used to model survival and screening bene-
ﬁts and is based on continuous tumor growth. It consists of four major components:
population, natural history, screening, and treatment, where the natural history com-
ponent is based on a cohort version of the MISCAN-Fadia model. This is illustrated
in Figure 9.
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Figure 9: The two MISCAN-Fadia simulation models used for producing the base case
results. Figure from Sita Y. G. L. Tan et al. [12]
2.2 Assigning a distribution
The growth rate in cancer mammae tumors is very individual. This makes assigning
one speciﬁc model to the growth hard. A much used model is that of exponential
growth. Since a growing tumor, slow or fast, is at some point restricted by conditions in
the host (immunologic response, vascular supply etc.), it is natural to consider models
that "decelerate". The Gompertz and logistic distribution satisfy this condition.
Spratt et. al. [4] investigate these three distributions, with diﬀerent parameters,
for their ﬁt to cancer mammae tumor growth data.
Exponential The exponential model suggests that a tumor increases in size at a
constant rate without any growth deceleration until death of the host. This model
gives the worst ﬁt to the data tested by Spratt et. al.
V (t) = Vcell · etκ , (1)
where V (t) is the tumor volume at time t, κ is the relative growth rate and Vcell is
the volume of one cell, i.e. Vcell = V (0).
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Gompertz The next model considered is the Gompertz model. The general form
is
V (t) = Vcell · e(1−e−αt)β/α , (2)
where α and β are parameters describing the rate of decay of the relative growth rate
and the relative growth rate it self.
It can be shown that:
Vmax = lim
t→∞
V (t) = Vcell · e(
β
α) .
Inserting this into equation 2:
V (t) = Vmax · e[e(−αt) · (
β
α)] .
Vmax is estimated to be 2
40 cells and the volume of one cell is estimated to be
1 · 10−6 mm3 by Spratt et al. [4].
This model demonstrates decelerating growth, and gives a decent ﬁt to the data.
Generalized logistic In the logistic model, tumor growth for small tumors is nearly
exponential, but "breaks" the growth as the tumors becomes larger.
The generalized model satisﬁes:
d(V (t))
dt
= κ(t) · V (t) · g(t, V (t)) ,
where κ(t) is the relative growth rate and g(t, V(t)) is a size dependent interaction
term.
Several forms of this equation have been studied. Skekhan [13] used the following
approach. Let
g(t, V (t)) = 1−
(
V (t)
Vmax
)N
.
As the volume of the tumor V (t) increases, 1−
(
V (t)
Vmax
)N
decreases and the tumor
growth is restricted. Assuming the relative growth rate, κ(t), and the environmental
carrying capacity (which is the maximum tumor size), Vmax, to be constant, the
following form of the logistic equation results:
dV (t)
dt
= V (t) · κ ·
(
1−
(
V (t)
Vmax
)N)
.
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The solution to this equation for N > 0 is
V (t) = Vmax ·
[
1 + e(−N(κt+c))
](− 1N ) ,
where
c =
(
− 1
N
)
ln
[(
Vmax
Vcell
)N
− 1
]
.
Inserting c into V(t) we get:
V (t) = Vmax
(
1 + e
−N
(
κ·t− ( 1N ) ln
[(
Vmax
Vcell
)N−1]))(− 1N )
=
Vmax
(1 + [(Vmax
Vcell
)N − 1] e−Nκt) 1N . (3)
Equation 3 with N = 4 is shown by Spratt et. al. [4] to give the best ﬁt to cancer
mammae tumor growth data.
This is the form used by Weedon-Fekjær et. al. [1] and which will be used further
in this thesis.
2.3 Diameter of a tumor
When a tumor is detected and removed, either after clinical or mammography detec-
tion, its size is measured as a diameter, assuming it is ball shaped. From equation
3 we know how the volume of a cancer mammae tumor develops and we know the
formula for the volume of a ball
V (t) =
4
3
pi
[
X(t)
2
]3
where X(t) is the diameter of a tumor at time t.
Because volume is a measurement that is hard to visualize, it may be easier to
conceive the size of a tumor if given the diameter.
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Solving for X(t):
4
3
pi
[
X(t)
2
]3
=
Vmax
(1 + [(Vmax
Vcell
)
1
4 − 1]e− 14κt)4[
X(t)
2
]3
=
3 · Vmax
4pi · (1 + [(Vmax
Vcell
)
1
4 − 1]e− 14κt)4
X(t) = 3
√
6 · Vmax
pi · (1 + [(Vmax
Vcell
)
1
4 − 1]e− 14κt)4 . (4)
Using equation 4, the calculation of tumor growth can be made using only diam-
eter.
The maximum diameter of a tumor Xmax is lim
t→∞
X(t) = 128 mm.
2.4 The growth rate κ
In the equation for cancer mammae tumor growth (4), κ is the relative, and indi-
vidual, growth rate. Following Weedon-Fekjær et. al. [1], it is assumed that κ varies
between individuals according to the log normal distribution (5). Given the underly-
ing parameters µ and σ2 , pseudo random numbers from the log normal distribution
can be generated using the function rlnorm in R. These parameters were estimated
by Weedon-Fekjær et. al. [1] and are shown in Table 4.
Recall here that the log normal distribution has the following density function
f(x;µ, σ) =
1
xσ
√
2pi
e−
(ln(x)−µ)2
2σ2 , (5)
which gives E[X] = eµ+
σ2
2 and Var[X] = (eσ
2 − 1)e2µ+σ2 .
Table 4: Estimated parameters of the log normal distribution for the growth rate κ,
estimated by Weedon-Fekjær et. al.
µ σ
50 - 59 1.38 1.36
60 - 69 0.70 1.18
All ages 1.07 1.31
To visualize the eﬀect of the diﬀerent values of the parameters, Figure 10 shows
tumor growth calculated by equation (4) for the expected value of κ in the considered
age groups. As seen, there is a big diﬀerence in average tumor growth. The two lines
in each color, indicate the average simulated κ and the average simulated κ after
truncation, described in the next paragraph.
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Table 5: Mean and standard deviation of the log normal distribution with parameters
from table 4 and simulated values based on 1 000 000 simulations for the truncated
distribution.
Expected Mean (eµ+
σ2
2 ) SD (
√
(eσ2 − 1)e2µ+σ2)
50 - 59 10.02217 23.19711
60 - 69 4.039819 7.025683
All ages 6.876089 14.6878
Simulated Mean SD
50 - 59 8.538821 12.68382
60 - 69 3.974879 6.209643
All ages 6.337193 10.01364
The log normal distribution with its parameters estimated by Weedon-Fekjær et
al. [1], has a heavy tail. Figure 11(a) shows 40 000 realizations of the log normal
distribution and as seen, though most values are smaller then 100, some are very
large. These large values of κ correspond to tumors that grow unrealistically fast.
In Figure 11(b) growth of tumors with κ = [100, 150, 200, 250] are shown. As an
example, a tumor with κ = 250 (blue) will grow from size 0 mm to Xmax = 128 mm
in three months. This is not realistic.
To remove these unrealistic values, a truncated log normal distribution is used.
Somewhat arbitrarily we chose to truncate at the value 100 for κ. In practice, each
drawn value of κ is checked. If it is larger then 100, a new value is drawn until a value
below 100 is obtained. Since these large values are rare, the mean after truncation is
hardly changed. A simulation of 1 000 000 realizations of κ, showed that the mean
changed from 6.876 to 6.337 after removing values of κ larger than 100.
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Figure 10: The tumor growth curves for the mean value of κ before and after trun-
cation for all considered age groups. The solid lines show the non-truncated values,
while the dotted lines show the growth curves after truncation. Blue: 50-59, red: 60-69
and green: all.
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Figure 11: a) 40 000 realizations of κ with µ = 1.07 and σ = 1.31 and b) tumor
growth curves for κ = [100, 150, 200, 250]
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Figure 12: The screening test sensitivity function, S(X). Blue: 50-59, red: 60-69 and
green: all.
2.5 Sensitivity of screening tests
The screening test sensitivity (STS) is a measure of how likely it is to ﬁnd a tumor
of a given size at screening. Since larger tumors are easier to ﬁnd on mammography
screening, it is natural to use a function that increases with increasing tumor size. A
logistic function is used by Weedon-Fekjær et. al. [1] to describe STS.
More preccisely, STS, the probability of ﬁnding a tumor with diameter X (in mm)
at screening, is deﬁned as
S(X) =
exp
(
X − β2
β1
)
1 + exp
(
X − β2
β1
) , (6)
where β1 deﬁnes how fast sensitivity increases by tumor size and β2 relates STS to
tumor size. β1 and β2 have been estimated using maximum likelihood by Weedon-
Fekjær et. al. [1]. The estimated values of β1 and β2 for the diﬀerent age groups are
displayed in Table 6. The function is displayed in Figure 12 for the considered age
groups. As seen, the STS function is very similar for the diﬀerent age groups.
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Table 6: Parameters of the screening test sensitivity
β1 β2
All ages 1.47 6.51
50 - 59 1.50 6.33
60 - 69 1.46 6.65
2.6 Estimation of the parameters
In sections 2.4 and 2.5, parameters of the log normal distribution and the STS-function
were given. These parameters were all estimated with the maximum likelihood method
by Harald Weedon-Fekjær et al. [1]. The following model parameters, assumptions and
data were used:
Assumptions
• Tumor growth curves follow a generalized logistic function
• Tumor growth κ varies between individuals following a log normal distribution
• No regressive tumors; once a tumor starts growing it does not stop
• Screening test sensitivity (STS) is a continuous increasing function of tumor
size, following a logistic function
• Cancer incidence without screening, and size distribution of clinically detected
tumors, can be estimated from historic data, with an added correction for in-
crased use of HRT use.
Model parameters
• µ Tumor growth parameter
• σ Variation in tumor growth rates (log normally distributed)
• β1 Relating STS and tumor size
• β2 Deﬁning how fast STS increases with tumor size.
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Data
• Data on tumor sizes found at screening were collected from the NBCSP (1995-
2002)
• Observed cancer incidence and size distribution at screening and in the following
years were collected from NBCSP and Statistics Norway (1995-2002)
• Assumed tumor sizes at diagnoses without screening are from Haukeland hos-
pital, before the initiation of the screening program (1985-1994)
• The expected incidence of cancer mammae without screening was estimated
from time-trends using the Norwegian Cancer Registry data (1978-1997).
The likelihood function
L(µ, σ, β1, β2) =∏
all size groups i
P (observed number of cases at screening in diﬀerent size groups i | µ, σ, β1, β2) ·
∏
all observed intervals j
P (observed number of interval cancers j months after screening | µ, σ, β1, β2)
2.7 Clinical detection diameter
Cancer mammae tumors are not only found by mammography screening. A lot of
tumors are also found clinically. Clinical detection is mostly the result of a clinical
symptom, i.e. feeling a bump, felt by the patient or a doctor. When running a sim-
ulation of cancer mammae development, a distribution of clinically detected tumors
is needed. Since tumors removed are measured in diameter, it is natural to look for
a distribution that could describe these sizes. Data on tumor size of clinically found
tumors have been registered in Haukeland hospital, Norway, before the oﬃcial screen-
ing program started (1985 - 1994). These data can therefore be used to estimate an
underlying distribution of size of clinically found tumors. These data are illustrated
(as a smoothed curve) in Figure 13.
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Figure 13: The tumor size distribution of tumors found clinically at Haukeland hospi-
tal before the oﬃcial screening program started for the age group 'all'. Figure from Harald
Weedon-Fekjær et al. [1]
Figure 14, shows histograms of the data sorted by age groups and using bars of
length 5 mm corresponding to diameters 5, 10, 15 etc. It can be seen that measure-
ments of tumors are not accurate. Especially for large tumors, there are unrealistically
many observations in size groups 70, 80, 90 and 100, in comparison to groups 75, 85
and 95. This is likely to be a result of rounding to the nearest ten mm.
The data were ﬁtted to gamma distributions (7), with parameters estimated using
the method of moments described in section 3.1,
f(x; k, θ) =
1
θkΓ(k)
xk−1e
−x
θ for x > 0 , (7)
where k is the shape and θ is the scale parameter.
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Figure 14: The frequency of tumors found clinically in size groups of 5 mm and the
gamma distribution with estimated parameters. The red line is the gamma distri-
bution with the unadjusted parameters, while the blue line indicates the adjusted
results.
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Table 7: Parameters of the Gamma distribution
Shape (k) Scale (θ) Shape (adjusted) Scale (adjusted)
All ages 2.3 12.386 2.958 9.076
50 - 59 2.276 13.145 2.787 10.168
60 - 69 2.337 11.751 3.165 8.145
Table 7 shows the result of the parameter estimation. Two diﬀerent sets of pa-
rameters are considered; a shape/scale and an adjusted shape/scale parameter. The
adjusted parameters are based on data without using the values larger than 85 mm,
while the unadjusted ones are based on all available data. Looking at Figure 14 again,
two smoothed lines are plotted for each age group. The red line is the gamma dis-
tribution with the unadjusted parameters, while the blue line shows the adjusted
results. The unadjusted density (red) has a heavy tail to pick up the large detection
values, but fails to suﬃciently pick up the "normal" values. Tumors larger than 85
mm are ignored in the simulation because such tumors often are results of denial of
the patient. The adjusted parameters are used in the following.
3 Statistical methods
3.1 Method of moments
The method of moments, is a simple way of estimating parameters such as mean,
variance or median from a known distribution. For the gamma distribution in equation
7, this is done by equating the known expected moments, E[X] = kθ and V ar[X] =
kθ2, to the observed mean and variance and solving the equations.
kθ = X¯ ⇒ kˆ = X¯
θˆ
kθ2 =
1
n− 1
∑
i
(Xi − X¯)2 ⇒ θˆ =
1
n−1
∑
i(Xi − X¯)2
X¯
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3.2 Poisson process
The Poisson process is a stochastic process, counting the number of events in con-
tinuous time, for example telephone calls received by an oﬃce, the number of typing
errors or the arrival times of customers at a service center. In this process events must
occur according to the following properties:
The Poisson process has no memory; the number of outcomes occurring in one
time interval, or other unit of measurement used, is independent of the number of
events occurring in any other disjoint time interval.
The probability that a single outcome will occur during a very short time interval,
or other unit of measurement used, is proportional to the length of the time interval
and does not depend on the number of outcomes occurring outside this time interval.
The probability that more than one outcome will occur in a short time interval,
or other unit of measurement used, is negligible.
It is reasonable to assume that the initiation of cancer mammae in a population
of women follows a Poisson process.
The Poisson process is characterized by its rate parameter λ, which is the expected
number of events occurring per unit time. In 2006, there were 1064 new cancer cases
among the 520 196 Norwegian women aged 50 - 69. The simulation uses months as
time steps, which means approximately 89 new cases per month, among the 520 196
women. That means that the rate parameter λ = n · 89
520196
, where n is the number of
women in the simulation.
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Part II
Simulation
Introduction
The goal of this part, is to describe steps needed to make a realistic simulation of a
Norwegian female population.
4 R
R is a free, statistical software package for computing and graphics. It is a
GNU project which is similar to the S language and environment. R can be
considered as a diﬀerent implementation of S. There are some important
diﬀerences, but much code written for S runs unaltered in R. Many important sta-
tistical methods are pre-programmed in R. Some examples are linear and nonlinear
modeling, classical statistical tests, time-series analysis, classiﬁcation and clustering.
The pseudo random number generator from diﬀerent distributions is particularly im-
portant in the simulation of cancer mammae.
All simulations and plots in this paper are obtained using R.
5 How the simulation works
When the simulation is initiated, the population consists of 25 000 women, who are
all cancer free. A separate simulation is run for women in age groups 50-59, 60-69 and
both (50-69). These speciﬁc age groups are chosen because the estimated parameters
are based on data from these groups.
As the simulation is initiated, for each woman a latent growth rate κ and a clinical
detection diameter is drawn from the distributions given in section 2.4 and 2.7. Know-
ing the growth rate κ and at what size the tumor will be found clinically, equation 4
gives the full path of the tumor growth.
Since it is not realistic that all women in the population get cancer at the same
time, or even get cancer at all, the event that a women gets cancer is assumed to
follow a Poisson process. With the assumptions of the Poisson process, it follows that
new cases of cancer mammae are randomly distributed throughout the year. At each
time step (one month) in the simulation, a random selection of women get cancer.
This is drawn by the pseudo random number generator of the Poisson distribution,
rpois in R.
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For the three considered age groups, diﬀerent screening intervals are tested. These
intervals are:
• Screening every year
• Screening every other year
• Screening every three years
• Screening every ﬁve years
• Screening every ten years
When screening takes place, all women are entered and the probability that their
tumor (if one is present) is detected (STS) is calculated. This is described in more
detail in section 5.2.
5.1 Reaching a stationary distribution
Before a realistic simulation of screening can be made, the population needs to reach
a stationary state, meaning that the distribution of tumor sizes is approximately the
same at all time steps. To reach this state, the simulation must go through a burn-in
period.
As shown in section 2.4, some simulated values of κ may become very large and
are therefore ignored (truncated). On the other hand, a lot of values of κ are very
small. About 2% of the values are less than 0.2. Figure 15 shows tumors with small
values of κ growing for 100 years. As seen, a tumor with κ = 0.1 or κ = 0.2 is less
then 10 mm in diameter after 100 years.
These slow growing tumors are hence a problem when trying to reach a stationary
state. At every time step in the simulation, new tumors may be initiated. When a
very slow growing tumor is initiated, it will stay in the simulation for a long time
without being detected neither clinically nor at screening, because of its small size.
After many time steps, this will result in a large number of small, very slow growing
tumors. This prevents the simulation from reaching a stationary state as the number
of small tumors increases. The consideration of such tumors is also unrealistic, since
we are looking at women aged 50 years or older, and the expected lifespan of a
(Norwegian) woman is 81,5 years according to Statistisk sentralbyrå in 2008.
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Figure 15: Tumor growth curves for tumors with κ = [0.1, 0.2, 0.3, 0.4, 0.5]
This problem can not be solved with truncation as for the large values of κ, since
there are many slow growing tumors in the population. The solution to the problem
was to introduce a time limit. With a time limit, it is certain that no tumor will keep
growing unrealistically long. This is illustrated in Figure 16. Figure 16(a) shows all
tumors growing without a limit from time 0 and 16(b) shows the same tumors after
introducing a time limit.
The time limit was set to be normally distributed with parameters stated in Table
8. In practice, all tumors are given a time limit. If the tumor is not detected clinically
nor at screening, the tumor is removed from the simulation.
Table 8: Parameters of the normal distribution giving a time limit to tumors. The
time unit is months.
Mean (µ) SD (σ)
50 - 59 300 30
60 - 69 180 30
All ages 240 30
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Figure 16: The plot shows 400 randomly selected tumor growth curves all starting
at time 0. Each colored line represents the tumors growth curve for one woman. The
height indicates the size of the tumor and the length along the x-axis, describes how
long it takes before the tumor is found clinically. Age group 'all'.
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5.2 Screening
When the population has reached a stationary state, screening can take place in the
simulation. Screening occurs in the same month every year and the entire population
is screened in the same time step. Berit Damtjernhaug at the Cancer Registry of
Norway, found the true turnout on mammography screening to be 76.2% in Norway,
based on data from NBCSP (1996 - 2005) [14].
At screening, every woman has a mammography. The STS function, as given in
equation (6), is used to determine how likely it is that a tumor is detected. Since a
tumor is either found or not, the binomial distribution by the function rbinom in R,
with parameters n = 1 and p = STS, is used to decide whether a tumor is found or
not, after STS has been calculated.
At the lower end of the scale, for diameters close to 0, the STS function in equation
(6) does not work well. This is illustrated in Figure 12. If a tumor with diameter 0,
thus no tumor, is entered to equation 6, the probability is 0.0118 that it found on
mammography screening. Since most women do not have a tumor, this results in a
lot of positive tests when there is no tumor to be detected.
To mend this problem, the STS for all tumors less then 0.5 mm in diameter is set
to 0. This is reasonable since it is not likely that any tumor less than 0.5 in diameter
will be found at screening.
5.3 Saved time because of screening
Looking back to Figure 5, the idea behind mammography screening is to detect cancer
mammae tumors earlier than they would have been if not screened. An interesting
result is therefore to see how much earlier, if earlier at all, the tumors are actually
found if screened in the simulation.
To calculate how much time is saved with diﬀerent screening intervals, diﬀerent
simulations had to be run. For screening every year, all women were screened for the
ﬁrst time at t = 12 (months) after burn-in. Whether a tumor is detected or not, is
determined as described in section 5.2.
If a tumor is detected at screening, the time until detection is registered. This time
is then compared to the time it would have taken before the tumor would have been
found clinically, which can be computed using the gamma distributions described in
section 2.7 and the given value of κ. The diﬀerence in times is recorded as the saved
time for that woman.
In the case where there is no tumor, or the tumor is too small to be detected at
screening, the simulation moves on to the next screening and the process is repeated.
Large tumors will be detected in the interval between the screenings if it reaches its
clinical detection diameter in the interval.
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Part III
Results
6 Results from simulation
6.1 The size distribution of tumors
In section 5.1 the necessity for reaching a stationary state was discussed. Figures
17(a), 17(b) and 17(c) show tumor growth after the initiation by the Poisson process.
It looks as if the population is stable after 10 years.
The size distribution of tumors, after reaching a stationary state, at nine given
times in the age group 'all', are plotted in Figure 18. The times were randomly
selected, for t > 15 years (180 months), as the population then seems to be in a
stationary state. The plot only shows tumor sizes between 0 and 10 mm, because the
number of larger tumors is very low. The plots show similar curves, and it is therefore
reasonable to assume that a stationary state has been reached and that the values
originate from the same distribution. Other age groups show similar results.
The tumor sizes were ﬁtted to a gamma distribution (7). As in section 2.7, param-
eters were estimated by the method of moments based on data from the nine selected
times. Table 9 shows the estimated mean and variance for all age groups and the
estimated parameter k and θ.
Table 9: Mean tumor size and variance (in mm) for all age groups and estimated
parameters of the gamma distribution.
Mean (kθ) SD (
√
kθ2)
50 - 59 3.035 7.641
60 - 69 1.831 5.268
All ages 2.449 6.469
k θ
50 - 59 0.158 19.234
60 - 69 0.121 15.156
All ages 0.143 17.093
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Figure 17: For the three considered age groups, growth curves initiated according to
the Poisson process are shown. The plots show 2000 randomly selected tumors. Each
colored line represents the tumor growth curve for one woman. The height indicates
the size of the tumor and the length along the x-axis, describes the time it takes
before the tumor is found clinically.
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Figure 18: The size distribution of tumors with diameter > 0 at random times during
the simulation.
39
When screening is introduced to the population, it is to be expected that the tumor
size distribution is changed. It is also reasonable to assume that the size distribution
is diﬀerent when screening is performed every year, compared to screening at longer
intervals. It is also of interest to ﬁnd the diﬀerence in size distributions before and
after screening.
A simulation to determine these distributions was made. Tables 10 and 11 show
the results. The gamma distribution was found to give a very good ﬁt also for this
size distribution.
Table 10 shows the estimated mean, variance and parameters one time step before
screening. The distribution before the ﬁrst screening is assumed to follow the distri-
bution of a stationary population without screening and these data are therefore not
included here. For all consecutive screenings (2nd, 3rd, 4th, and so on), the distribu-
tion is assumed to be the same. The calculation is made in the time step (one month)
before screening takes place in the simulation.
As expected, the mean tumor size before screening becomes larger with infrequent
screening. This is reasonable, because tumors have more time to grow between each
screening. Comparing the last lines in Table 10, it can be seen that for screening every
ﬁve or every ten years, the mean tumor size is almost as large as in a population
without screening.
It is interesting to see that the parameter k, the shape parameter, is very similar
for all the considered screening frequencies. The Coeﬃcient of variation, CV , in the
gamma distribution is 1
k
= (cv)2. Since k is very similar for all screening frequencies,
within each age group, the CV is also similar.
Table 11 shows the same values after screening. It is interesting to see that the
tumor size distribution after screening is very stable in diﬀerent screening frequencies.
This is a result of how mammography screening works. Since a tumor can ﬁrst be seen
on a mammography x-ray after reaching a certain size, the size distribution of tumors
found at screening will be very similar, independent of the screening frequency.
The diﬀerence between the age groups can also be seen from the tables. Tumors
in younger women (50 - 59) are larger, on average, and have a higher variance than
in older women, especially before screening.
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Table 10: Mean tumor size and SD (in mm) one time step (one month) before
screening for all age groups and screening intervals, and estimated parameters of the
gamma distribution.
Age group
50-59 60-69 All
Screening frequency Mean - SD Mean - SD Mean - SD
Every year 1.293 - 3.167 0.953 - 2.613 1.187 - 3.010
Every two years 1.919 - 5.032 1.451 - 4.039 1.682 - 4.343
Every three years 2.309 - 5.794 1.629 - 4.463 2.060 - 5.199
Every ﬁve years 2.629 - 6.426 1.871 - 5.265 2.322 - 5.878
Every ten years 2.964 - 7.581 1.900 - 5.201 2.755 - 7.078
Never 3.035 - 7.641 1.831 - 5.268 2.449 - 6.469
Age group
50-59 60-69 All
Screening frequency k - θ k - θ k - θ
Every year 0.166 - 7.759 0.133 - 7.165 0.155 - 7.631
Every two years 0.145 - 13.186 0.129 - 11.245 0.150 - 11.211
Every three years 0.159 - 14.543 0.133 - 12.224 0.157 - 13.116
Every ﬁve years 0.167 - 15.702 0.126 - 14.814 0.156 - 14.877
Every ten years 0.152 - 19.391 0.133 - 14.232 0.151 - 18.181
Never 0.158 - 19.234 0.121 - 15.156 0.143 - 17.093
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Table 11: Mean tumor size and variance (in mm) one time step (one month) after
screening for all age groups and screening intervals, and estimated parameters of the
gamma distribution.
Age group
50-59 60-69 All
Screening frequency Mean - SD Mean - SD Mean - SD
Every year 0.784 - 1.628 0.605 - 1.386 0.732 - 1.593
Every two years 0.839 - 1.745 0.662 - 1.522 0.758 - 1.570
Every three years 0.868 - 1.774 0.659 - 1.517 0.788 - 1.685
Every ﬁve years 0.876 - 1.775 0.667 - 1.516 0.781 - 1.679
Every ten years 0.828 - 1.823 0.664 - 1.526 0.748 - 1.558
Age group
50-59 60-69 All
Screening frequency k - θ k - θ k - θ
Every year 0.232 - 3.381 0.190 - 3.179 0.211 - 3.464
Every two years 0.231 - 3.626 0.189 - 3.500 0.233 - 3.250
Every three years 0.239 - 3.624 0.189 - 3.487 0.219 - 3.599
Every ﬁve years 0.244 - 3.597 0.193 - 3.446 0.216 - 3.607
Every ten years 0.206 - 4.014 0.189 - 3.506 0.230 - 3.242
6.2 Clinical detection
In section 2.7, parameters of the gamma distribution were estimated from real data to
be used in simulation of a clinical detection size. Figures 19(a), 19(b) and 19(c) show
the estimated gamma distribution of size of clinically detected tumors (red) and the
tumor size distribution found in the simulation (blue), for all age groups. To make
comparison easier, Figure 13 from section 2.7 is repeated as Figure 19(d).
Figure 19(d) shows the non-parametrically estimated tumor size distribution of
tumors found clinically before the oﬃcial screening program started. As can be seen,
the estimated gamma distribution (red) and the tumor size distribution found in the
simulation (blue) are very similar. The tumor size distribution found in the simulation
is also very similar to the size distribution estimated from the observed data. This is
reasonable, since the gamma distribution is estimated from the Haukeland data and
the simulated values are drawn from this gamma distribution.
In the simulation, a tumor is detected clinically once its size is larger or equal to
the detection size drawn from the gamma distribution. This discretization of the time
steps causes the slight bias seen in Figure 19.
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(d) All, form Haukeland hospital.
Figure 19: The estimated gamma distribution of size of clinically detected tumors in
red compared to the size distribution found in the simulation in blue.
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6.3 Detection at screening
In section 1.7 screening by mammography was described. Figure 6 showed the size
distribution of tumors found at screening, based on data from the NBCSP (collected
1995-2002). The ﬁgure is repeated as Figure 20(d). These data were strictly from
the ﬁrst appearance at screening of women aged 50-69 reporting no earlier screening
history.
When running the simulation, the "women" entering the ﬁrst screening have the
same properties; it is their ﬁrst appearance at screening and they have not been
screened before.
The size distribution of tumors found at screening is very dependent on the STS-
function, since this function decides which tumors are detected at screening.
Comparing Figure 20(c) and 20(d), it can be seen that the two densities are similar.
Unlike the clinical detection size, which is estimated from observed cancer mammae
data, the detection size at screening is just observed in the simulation. Seeing that the
size distribution in the simulation is similar to the observed data from the NBCSP,
is therefore a good indication that the simulation, and especially the STS-function,
is working properly.
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Figure 20: Size distribution of tumors found at ﬁrst screening. (a), (b) and (c) are
from the simulation, while (d) is from the observed data (NBCSP)
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6.4 Reduction in number of cancer cases
Table 12 shows the number of cancer cases found at various screenings in the simu-
lation.
As seen, the number of tumors found at the ﬁrst screening is similar within each
age group. This is as expected as a stationary state is reached before the ﬁrst screening.
The table also shows that more tumors are detected at screening in younger women
in the ﬁrst screening and also in the following rounds of screening. This is natural as
tumors in younger women grow faster, on average.
With screening every year, the number of tumors found at screening stabilizes
on a lower level than with more infrequent screening. This is in accordance with the
results found in section 6.1.
Figures 21 and 22 show tumor growth curves with and without screening for
diﬀerent screening intervals. The grey lines indicate when screening is initiated and
when it ends, respectively. How many screenings that take place between the to grey
lines, is determined by the screening frequencies. For practical purposes, the plot for
screening interval 'every ﬁve years' is left out.
Figure 21(a) shows the situation for screening every year. As can be seen, a lot of
tumors are removed at the ﬁrst screening; the colored lines are removed at the ﬁrst
grey line. Also, in the time interval where screening is active, between the two grey
lines, tumors are smaller (the colored lines are lower). This indicates that tumors
are found smaller (and thus earlier) than they would have been if not screened. For
screening every two years, shown in 21(b), the results are similar, but the reduction
in tumor size is less.
When screening is less frequent, the diﬀerence between the growth curves with
and without screening become more alike because tumors have more time to grow
between each screening.
Another interesting point, is to see how fast after the last screening the tumor
growth curves are back on the same level as when no screening was performed.
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Table 12: Number of cancer cases found at the ﬁrst six screenings for the considered
screening frequencies and age groups
Age group 50-59
Screening freq. 1. screen 2. screen 3. screen 4. screen 5. screen 6. screen
Every year 1233 699 664 688 617 648
Every two years 1200 928 923 881 832 759
Every three years 1207 1033 1044 983 916 824
Every ﬁve years 1220 1146 1088 1054 904 -
Every ten years 1202 1148 1142 - - -
Age group 60-69
Screening freq. 1. screen 2. screen 3. screen 4. screen 5. screen 6. screen
Every year 842 566 512 503 481 487
Every two years 846 720 690 673 687 602
Every three years 831 825 726 741 771 655
Every ﬁve years 866 799 824 730 646 -
Every ten years 825 792 792 - - -
Age group All
Screening freq. 1. screen 2. screen 3. screen 4. screen 5. screen 6. screen
Every year 1049 619 635 550 614 630
Every two years 1026 874 803 820 801 741
Every three years 1018 909 973 882 884 763
Every ﬁve years 1089 1022 974 885 854 -
Every ten years 1058 1022 973 - - -
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(a) Screening every year
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(b) Screening every two years
Figure 21: Tumor growth curves with or without screening. Each colored line repre-
sents the tumor growth curve for one woman. The height indicates the size of the
tumor and the length along the x-axis, describes the time it takes before the tumor is
found clinically. The grey, vertical lines indicate when screening is initiated and when
it ends, respectively. Age group 'all'.
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(a) Screening every three years
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(b) Screening every ten years
Figure 22: Tumor growth curves with or without screening. Each colored line repre-
sents the tumor growth curve for one woman. The height indicates the size of the
tumor and the length along the x-axis, describes the time it takes before the tumor is
found clinically. The grey, vertical lines indicate when screening is initiated and when
it ends, respectively. Age group 'all'.
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6.5 Values of the growth rate κ
Table 13 shows the average value of the growth rate κ for tumors found clinically and
at screening for all age groups and screening frequencies.
The results show that tumors found clinically mostly have larger values of κ than
tumors found at screening. An exception can be seen in the age group '60 - 69', where
values of κ are larger in tumors found at screening than in tumors found clinically for
screening frequencies every and every two years. This is realistic because an aggressive
tumor (large κ) has a shorter MST and is more likely to be found clinically before
screening takes place.
The table also shows that more infrequent screening results in somewhat less
aggressive tumors being found on screening. If screening takes place every ten years,
even less aggressive tumors will have time to become so large that they are found
clinically and only slower growing tumors will be detected at screening.
The diﬀerence between the age groups, can be explained by the fact that the
average κ in the age groups is very diﬀerent. Table 5 showed the mean of κ and it
can be seen that the mean is similar to the values of detected tumors.
Table 13: Average growth rate κ for tumors found clinically and at screening
Age group
50-59 60-69 All
Screening frequency Clinical - Screening Clinical - Screening Clinical - Screening
Every year 10.6389 - 6.0522 3.6721 - 4.4488 7.1077 - 5.3299
Every two years 10.3601 - 5.2514 3.9041 - 4.0512 7.1899 - 4.5916
Every three years 9.7859 - 4.9654 3.9779 - 3.9054 7.0135 - 4.3325
Every ﬁve years 9.5258 - 4.6966 3.9708 - 3.8498 6.8169 - 4.2813
Every ten years 9.1486 - 4.4453 3.9713 - 3.8992 6.6280 - 4.1179
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6.6 Saved time because of screening
In section 5.3 the method of recording saved time was presented. In Tables 14 and
15, two diﬀerent results are given.
Table 14 shows measurements of time saved for tumors that were actually found at
screening. Thus, tumors that are found clinically in the intervals between screenings
are not considered. These results are interesting, and give a realistic view, because a
woman who has found a tumor clinically (in an interval) is not likely to participate
in the normal screening program.
Table 15 shows measurements of time saved for all tumors and the standard de-
viation of these measurements.
As both tables show, the most time is saved if all women are screened every year
and less time is saved with more infrequent screening. This is as expected. There is a
slight diﬀerence between the age groups. Somewhat more time is saved by screening
older women, which is likely to be a result of tumors growing slower in this age group.
The mean sojurn time (MST), described in section 1.7, tells us how long, on
average, a tumor is of screening detectable size, before it is found clinically. The MST
is estimated to 34.8 months (2.9 years) for the age group 'all' by Harald Weedon-
Fekjær et al. [1].
The numbers in Table 14 are based on measurements of the time until a tumor
would be found clinically, minus the time until the tumor is found on screening, given
that it is not found clinically before screening. Table 14 shows that a tumor found at
screening would be found clinically, on average, 19 months later, with screening every
year in the age group 'all'. This is a reasonable result, because it implies that tumors,
on average, are found approximately in the middle of the MST-interval.
The numbers in Table 15 are based measurements of the time until a tumor is
found clinically, minus the time until the tumor would be found on screening. If the
tumor is found later at screening than it would have been clinically, the result is a
negative number and no time is saved by screening. Table 15 shows that a tumor found
at screening would be found clinically, on average, 15 months later, with screening
every year in the age group 'all'. The standard deviations are, though, fairly high.
For screening every year, it can be seen from the tables that the most time can
be saved because of screening in all age groups. This is reasonable, because frequent
screening allows less tumors to grow to clinically detection size. When screening is
reduced to every second year, a lot less time is saved because of screening. The tumors
that are actually found, are found about ten months earlier than they would have
been without screening, while on average of all tumors only about 5 months is saved
(dependent on the age group).
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Screening every three years allows tumors to be found about eight months earlier
if found at screening, but on average, tumors are found just as early clinically (the
time until it would have been found clinically, minus the time until a tumor is found
on screening is about zero).
If screening is only every ﬁve or every ten years, some time will still be saved
if a tumor is found at screening, but the tumors will, on average, be found earlier
clinically (the time until it would have been found clinically, minus the time until a
tumor is found on screening is, on average, less than zero).
In general, the tables show that for tumors actually found on screening, some
time is saved compared to no screening (when all tumors are found clinically). But,
with screening less frequent than every two years, tumors are found as early or earlier
without screening.
Table 14: Average saved time (in months) because of screening, with diﬀerent screen-
ing intervals, for tumors being found on screening before being found clinically.
Age group
Screening frequency 50 - 59 60 - 69 All
Every year 19.9149 20.1934 19.0896
Every two years 10.0587 9.8625 9.4820
Every three years 8.81391 8.5083 8.3353
Every ﬁve years 6.64001 6.2254 6.1426
Every ten years 3.67423 3.6349 3.4334
Table 15: Average saved time (in months) and standard deviation because of screening,
with diﬀerent screening intervals. Negative numbers indicate that tumors will be found
clinically earlier than at screening.
Age group
Screening frequency 50 - 59 60 - 69 All
Mean - SD Mean - SD Mean - Sd
Every year 15.873 - 33.873 16.688 - 29.730 15.022 - 29.105
Every two years 4.367 - 20.874 6.046 - 19.902 4.836 - 19.725
Every three years 0.477 - 20.319 3.127 - 19.103 1.401 - 19.505
Every ﬁve years -6.771 - 23.268 -3.276 - 21.254 -5.574 - 22.132
Every ten years -23.577 - 36.820 -17.356 - 34.198 -21.475 - 35.759
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Part IV
Discussion and conclusion
This paper takes advantage of present technology, both hardware and software, to
simulate a large, synthetic population where issues normally not available for research
because of practical limitations or ethical concerns, can be tested. The results from
the simulation were compared to observed data on cancer mammae, and were found
to be realistic and expected, verifying the underlying model and parameters estimated
by Harald Weedon-Fekjær [1].
There are some aspects not covered in this paper. The results given are only an
indication of which tumors are seen on a mammography x-ray; no further diagnosis
is given. There is also no connection between how much time is saved because of
screening and mortality rates. A measure of such would be a large improvement of
the simulation study.
In the model, the individual growth rate κ and the gamma distributed clinical
detection size are assumed to be independent. It would be interesting to ﬁnd out if
this assumption holds. My conjecture, is that an aggressive tumor (large κ) is found
earlier clinically, and thus smaller, than a less aggressive (small κ) tumor.
A possible weakness is the assumption that a cancer mammae tumor is ball shaped.
Tumors do not have perfect ball shapes. Also, the diameter of a tumor is roughly
measured (as seen in the data from Haukeland hospital) and this might cause bias to
the estimated parameters, and therefore to the calculations in this paper.
Several types of size distributions of tumors were found to be well ﬁt with a gamma
distribution. The size distribution of tumors found at screening in the simulation was
similar to observed data from NBCSP. Because this distribution is based on the STS-
function, its similarity with real life observations is a strong indication that both the
simulation and the STS-function work well.
As expected, the size distribution of tumors found clinically in the simulation
followed the same distribution as the observed data from Haukeland hospital. Also,
the simulation found a strong reduction in number of cancer cases with frequent
screening (every- or every second year), while less frequent screening results in a
lower reduction.
The distribution of the growth rate κ varies between the age groups. It was found
that tumors detected on screening, on average, are less aggressive (smaller value of κ)
than tumors found clinically, except for screening every- and every two years in the
age group '60 -69'.
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An important question is how much time can be saved, on average, because of
screening with diﬀerent screening intervals. Two aspects were given; one only consid-
ering the tumors actually found at screening while the other included both tumors
found clinically and at screening. The results were somewhat mixed. With screening
every year, for women aged 50 - 69 (age group 'all'), tumors are found 15 months
earlier than without screening, on average, with a standard deviation of 29 months,
when looking at the whole picture. Because of this large standard deviation, much
more than 15 months can be saved for some women, but also a lot less in others.
For screening every second year, which is the frequency of the NBCSP, tumors
are found a little less than 5 months earlier because of screening, with a standard
deviation of about 20 months. Screening every three years only allows for 1.5 months
earlier detection, with a standard deviation of 19.5 months.
When screening is even less frequent, tumors are, on average, found earlier clini-
cally than at screening.
It is interesting to see these results of time saved by screening in the light of the
results of the growth rate κ. The values of κ in the tumors found at screening were,
with two exceptions in the age group 60 - 69, smaller than in tumors found clinically.
Especially in younger women, the diﬀerence in growth rate is large. This means, that
the tumors found at screening grow slower than tumors found clinically, which is
natural to assume. Considering that the tumors found at screening are slow growing,
and that the time saved, on average, by screening every two years like in the NBCSP
is only about 5 months, there is reason to further investigate this matter.
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Part VI
Appendix
7 R-code
All codes are stated for the age group 'all', as the code for the other age group is
similar.
7.1 Initiation of the simulation
### Initiating population ###
n = 25000
time_tot = 50
time = seq(from=0, to=time_tot, by=0.0833333)
months = length(time)
screen_years = 25
### Cancer tumor growth ###
tumorgrowth = matrix(data=NA, nrow=months, ncol=n)
tumorgrowth_det = matrix(data=NA, nrow=months, ncol=n)
tumor = rep(NA, times=months)
lambda = 2.166667e-08
max_time = rnorm(n=n, mean = 240, sd=30)
alfa1 = 1.07
alfa2 = 1.31
k = rlnorm(n=n, meanlog=alfa1, sdlog=alfa2)
k_max = 100
det_diam = rgamma(n=n, shape=2.958, scale = 9.076)
det_value = rep(NA, times=n)
### Other parameters ###
vmax = 4/3 * pi * (128/2)^3
vcell= 1*10^(-6)
beta2 = 6.51
beta1 = 1.47
y <- matrix(rep(1:months,n),months)/12
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### Simulation (age group all) ###
### Making sure that kappa is not unrealistically large ###
for(i in 1:n) {
while (k[i] > k_max) (k[i] = rlnorm(n=1, meanlog=alfa1, sdlog=alfa2))
}
### A simulation of all potential tumors ###
for(i in 1:n) {
for(t in 1:months){
tumor[t]= 2*((3*vmax)/(4*pi*((1 + ((vmax/vcell)^0.25 - 1)*
exp(-0.25*k[i]*time[t]))^4)))^(1/3)
}
tumorgrowth[,i] = tumor
}
tumorgrowth_det = tumorgrowth
### Checking where all the tumors will be detected clinically ###
for (i in 1:n) {
for(t in 1:months){
if (tumorgrowth_det[t,i] > det_diam[i])
(det_value[i] = tumorgrowth_det[t,i])
& (tumorgrowth_det[(t:months),i] = 0)
}
}
### Taking out "old" tumors ###
for (i in 1:n) {
for (t in max_time[i]:months+1) {
tumorgrowth_det[t,i] = 0
}
}
7.2 Screening
### Screening frequency ###
a = 1
j = months - (screen_years*12 +1)
screen = seq(from= j+(a*12), to= months-(5*12+1) , by=a*12)
### Selection of cancer and cancer growth ###
pop = rep(0, times=n)
cancer = rep(0, times=n)
growth_no_screen = matrix(data=0, nrow=months, ncol=n)
growth_with_screen = matrix(data=NA, nrow=months, ncol=n)
tumor_dist = matrix(data=NA, nrow=months, ncol=n)
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screen_det = rep(0, times=n)
sts = rep(NA, times=n)
### Some people get cancer each month ###
for(t in 1:months){
cancer = rpois(n=n, lambda=(n*lambda))
for (i in 1:n) {
if (cancer[i] == 1) (pop[i] = 1) & (growth_no_screen[t:months,i]
= tumorgrowth_det[1:(length(t:months)),i])
}
}
pop_clin = pop
### Screening ###
### Assuming the first is screening at time j ###
for (i in 1:n) {
sts[i] = exp((growth_no_screen[j,i] - beta2)/beta1) /
( 1 + exp((growth_no_screen[j,i] - beta2)/beta1))
}
for (i in 1:n) {
if (sts[i] < 0.016489) (sts[i] = 0)
}
### Detection according to a binomial distribution (1, sts[i]) ###
tumor_detected = rep(NA, times=n)
for(i in 1:n) {
tumor_detected[i] = rbinom(n=1, size=1, prob=sts[i])
}
### Removing the tumors that were detected at screening at time j ###
for(i in 1:n) {
if (tumor_detected[i] == 1) (growth_with_screen[(j+1),i] = 0) & (pop[i] = 0)
& (tumor_dist[j,i] = growth_no_screen[j,i]) & (screen_det[i] = 1)
else (growth_with_screen[(j+1),i] = growth_no_screen[(j+1),i])
}
growth_with_screen[0:j,] = growth_no_screen[0:j,]
for (i in 1:n) {
if (pop[i] == 1) (growth_with_screen[(j+2):screen[1],i] =
growth_no_screen[(j+2):screen[1],i])
else (growth_with_screen[(j+1):months,i] = 0)
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}for (i in 1:n) {
sts[i] = exp((growth_no_screen[j,i] - beta2)/beta1) /
( 1 + exp((growth_no_screen[j,i] - beta2)/beta1))
}
for (i in 1:n) {
if (sts[i] < 0.016489) (sts[i] = 0)
}
tumor_detected = rep(NA, times=n)
for(i in 1:n) {
tumor_detected[i] = rbinom(n=1, size=1, prob=sts[i])
}
### How many people have cancer before screening? ###
cases_before[1] = sum(pop)
total_volume_before[1] = sum(growth_no_screen[j,])
for(i in 1:n) {
if (tumor_detected[i] == 1) (growth_with_screen[(j+1),i] = 0) & (pop[i] = 0)
& (tumor_dist[j,i] = growth_no_screen[j,i]) & (screen_det[i] = 1)
else (growth_with_screen[(j+1),i] = growth_no_screen[(j+1),i])
}
### How many people have cancer after screening? ###
growth_with_screen[0:j,] = growth_no_screen[0:j,]
for (i in 1:n) {
if (pop[i] == 1) (growth_with_screen[(j+2):screen[1],i] =
growth_no_screen[(j+2):screen[1],i])
else (growth_with_screen[(j+1):months,i] = 0)
}
cases_after[1] = sum(pop)
total_volume_after[1] = sum(growth_with_screen[j+1,])
gc()
### Screening (for all other then the first and last) ###
for (v in 1:(length(screen)-1)) {
sts = rep(NA, times=n)
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for (i in 1:n) {
sts[i] = exp((growth_with_screen[screen[v],i] - beta2)/beta1) /
( 1 + exp((growth_with_screen[screen[v],i] - beta2)/beta1))
}
for (i in 1:n) {
if (sts[i] < 0.016489) (sts[i] = 0)
}
tumor_detected = rep(NA, times=n)
for(i in 1:n) {
tumor_detected[i] = rbinom(n=1, size=1, prob=sts[i])
}
### Removing the tumors that were detected at screening at time screen[v] ###
for(i in 1:n) {
if (tumor_detected[i] == 1) (growth_with_screen[(screen[v]+1),i] = 0) & (pop[i] = 0)
& (tumor_dist[screen[v],i] = growth_with_screen[screen[v],i]) & (screen_det[i] = 1)
else (growth_with_screen[(screen[v]+1),i] = growth_no_screen[(screen[v]+1),i])
}
### How many people have cancer after screening? ##
for (i in 1:n) {
if (pop[i] == 1) (growth_with_screen[(screen[v]+2):screen[v+1],i] =
growth_no_screen[(screen[v]+2):screen[v+1],i])
else (growth_with_screen[(screen[v]+1):months,i] = 0)
}
}
### What happens after the last screening? ###
sts = rep(NA, times=n)
for (i in 1:n) {
sts[i] = exp((growth_with_screen[screen[length(screen)],i] - beta2)/beta1) /
( 1 + exp((growth_with_screen[screen[length(screen)],i] - beta2)/beta1))
}
for (i in 1:n) {
if (sts[i] < 0.016489) (sts[i] = 0)
}
tumor_detected = rep(NA, times=n)
for(i in 1:n) {
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tumor_detected[i] = rbinom(n=1, size=1, prob=sts[i])
}
### Removing the tumors that were detected at screening at time screen[v] ###
for(i in 1:n) {
if (tumor_detected[i] == 1) (growth_with_screen[(screen[length(screen)]+1),i] = 0)
& (pop[i] = 0) & (tumor_dist[screen[length(screen)],i] =
growth_with_screen[screen[length(screen)],i]) & (screen_det[i] = 1)
else (growth_with_screen[(screen[length(screen)]+1),i] =
rowth_no_screen[(screen[length(screen)]+1),i])
}
### How many people have cancer after screening? ###
for (i in 1:n) {
if (pop[i] == 1) (growth_with_screen[(screen[length(screen)]+2):months,i] = growth_no_screen[(screen[length(screen)]+2):months,i])
else (growth_with_screen[((screen[length(screen)]+1):months),i] = 0)
}
7.3 Calculations of time saved
### How much time is saved because of screening in the original simulation? ###
growth_time = rep(0, times=n) ng
for (i in 1:n) {
if (screen_det[i] == 1)
(for (t in 1:months) { if (tumorgrowth[t,i] > 0)
( if (tumorgrowth[t,i] < det_diam[i])
(growth_time[i] = growth_time[i]+1)) } )
}
tumor_dist2 = rep(NA, times=n)
for (i in 1:n) {
xx = rep(NA, times=months)
if (screen_det[i] == 1) (xx = tumor_dist[,i]) & (xx = xx[!is.na(xx)])
& (tumor_dist2[i] = xx)
}
growth_time2 = rep(0, times=n)
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for (i in 1:n) {
if (screen_det[i] == 1)
(for (t in 1:months) { if (tumorgrowth[t,i] > 0) ( if (tumorgrowth[t,i]
<= tumor_dist2[i]) (growth_time2[i] = growth_time2[i]+1)) } )
}
growth_time[is.na(growth_time)] = 0
saved_time1 = growth_time - growth_time2
### How much time is saved for different screening intervals,
### compared to clinical finding ###
tumorgrowth_new = matrix(data=0, nrow=months, ncol=n)
for (i in 1:n) {
t = runif(1, 1, 600)
tumorgrowth_new[t:months,i] = tumorgrowth[1:length(t:months),i]
}
### Screening every year ###
new_time_total = 40
new_time = seq(from=0, to=new_time_total, by=0.0833333333)
new_months = length(new_time)
a = 1
new_screen = seq(from= a*12, to= new_months , by= a*12 )
new_sts = matrix(data=NA, nrow=new_months, ncol=n)
new_tumor_detected = matrix(data=0, nrow=new_months+1, ncol=n)
new_det = rep(0, times=n)
for (i in 1:n) {
for (t in new_screen) {
new_sts[t,i] = exp((tumorgrowth_new[t,i] - beta2)/beta1) /
( 1 + exp((tumorgrowth_new[t,i] - beta2)/beta1))
new_tumor_detected[t,i] = rbinom(n=1, size=1, prob=new_sts[t,i])
}
}
for (i in 1:n) {
for (t in new_screen) {
if (new_sts[t,i] < 0.016489) (new_sts[t,i] = 0)
}
}
63
for (i in 1:n) {
for (t in new_screen) {
if (new_tumor_detected[t,i] == 1)
(new_tumor_detected[t:new_months,i] = 1) & (new_det[i] = 1)
}
}
growth_time3 = rep(0, times=n)
for (i in 1:n) {
for (t in 1:new_months) { if (tumorgrowth_new[t,i] < det_diam[i])
(growth_time3[i] = growth_time3[i]+1)
}
}
growth_time4 = rep(0, times=n) # Time until tumors found at screening
for (i in 1:n) {
for (t in 1:new_months) { if (new_tumor_detected[t,i] == 0)
(growth_time4[i] = growth_time4[i]+1)
}
}
saved_time_int1 = growth_time3 - growth_time4
7.4 Calculations of κ
### Finding the distribution of kappa in tumors that are found clinically ###
total_pop = (pop_clin - screen_det)
kappa_clin = rep(NA, times=n)
for (i in 1:n) {
if (total_pop[i] == 1) (kappa_clin[i] = k[i])
}
kappa_clin1 = kappa_clin[!is.na(kappa_clin)]
### Finding the distribution of kappa in tumors that are found at screening ###
kappa_screen = rep(NA, times=n)
for (i in 1:n) {
if (screen_det[i] == 1) (kappa_screen[i] = k[i])
}
kappa_screen1 = kappa_screen[!is.na(kappa_screen)]
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